These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8214004)

  • 1. Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome.
    Medeiros LJ; Gelb AB; Wolfson K; Doggett R; McGregor B; Cox RS; Horning SJ; Warnke RA
    Am J Pathol; 1993 Oct; 143(4):1086-97. PubMed ID: 8214004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.
    Jesionek-Kupnicka D; Bojo M; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Jabłońska J; Kalinka-Warzocha E; Kordek R; Młynarski W; Robak T; Warzocha K; Lech-Maranda E
    Arch Immunol Ther Exp (Warsz); 2016 Jun; 64(3):225-40. PubMed ID: 26667793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.
    Möller P; Momburg F; Koretz K; Moldenhauer G; Herfarth C; Otto HF; Hämmerling GJ; Schlag P
    Cancer Res; 1991 Jan; 51(2):729-36. PubMed ID: 1985791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
    Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
    J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence.
    List AF; Spier CM; Miller TP; Grogan TM
    Leukemia; 1993 Mar; 7(3):398-403. PubMed ID: 7680400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MHC antigen expression in human oral squamous carcinoma cell lines.
    Mutlu S; Matthews JB; Midda M; Scully C; Prime SS
    J Pathol; 1991 Oct; 165(2):129-36. PubMed ID: 1744799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I and class II major histocompatibility complex antigens expression on human hepatocytes and hepatoma cells: an approach with high sensitivity and specificity.
    Chiu JH; Lui WY; Chang HM; Loong CC; Wu LH; Kao HL; Wu CW
    Cytometry; 1997 Dec; 30(6):317-23. PubMed ID: 9440824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.
    Rybski JA; Spier CM; Miller TP; Lippman SM; McGee DL; Grogan TM
    Leuk Lymphoma; 1991; 6(1):31-8. PubMed ID: 27457573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of the expression of major histocompatibility complex class II antigen, HLA-DR and -DQ, with recurrence of papillary thyroid cancer.
    Jo YS; Lee JC; Li S; Choi YS; Bai YS; Kim YJ; Lee IS; Rha SY; Ro HK; Kim JM; Shong M
    Int J Cancer; 2008 Feb; 122(4):785-90. PubMed ID: 17957790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
    Rimsza LM; Roberts RA; Miller TP; Unger JM; LeBlanc M; Braziel RM; Weisenberger DD; Chan WC; Muller-Hermelink HK; Jaffe ES; Gascoyne RD; Campo E; Fuchs DA; Spier CM; Fisher RI; Delabie J; Rosenwald A; Staudt LM; Grogan TM
    Blood; 2004 Jun; 103(11):4251-8. PubMed ID: 14976040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA class II antigen expression in human papillomavirus-associated cervical cancer.
    Glew SS; Duggan-Keen M; Cabrera T; Stern PL
    Cancer Res; 1992 Jul; 52(14):4009-16. PubMed ID: 1377602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms and effects of loss of human leukocyte antigen class II expression in immune-privileged site-associated B-cell lymphoma.
    Booman M; Douwes J; Glas AM; Riemersma SA; Jordanova ES; Kok K; Rosenwald A; de Jong D; Schuuring E; Kluin PM
    Clin Cancer Res; 2006 May; 12(9):2698-705. PubMed ID: 16675561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of major histocompatibility gene expression in human vascular smooth muscle cells.
    Warner SJ; Friedman GB; Libby P
    Arteriosclerosis; 1989; 9(3):279-88. PubMed ID: 2470342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression.
    van Houdt IS; Sluijter BJ; Moesbergen LM; Vos WM; de Gruijl TD; Molenkamp BG; van den Eertwegh AJ; Hooijberg E; van Leeuwen PA; Meijer CJ; Oudejans JJ
    Int J Cancer; 2008 Aug; 123(3):609-15. PubMed ID: 18498132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites.
    Riemersma SA; Jordanova ES; Schop RF; Philippo K; Looijenga LH; Schuuring E; Kluin PM
    Blood; 2000 Nov; 96(10):3569-77. PubMed ID: 11071656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma.
    Stopeck AT; Gessner A; Miller TP; Hersh EM; Johnson CS; Cui H; Frutiger Y; Grogan TM
    Clin Cancer Res; 2000 Oct; 6(10):3904-9. PubMed ID: 11051236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation of canine malignant lymphomas in the nude and SCID mouse.
    Baron T; Doré JF
    In Vivo; 1992; 6(1):77-9. PubMed ID: 1627746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
    Bijen CB; Bantema-Joppe EJ; de Jong RA; Leffers N; Mourits MJ; Eggink HF; van der Zee AG; Hollema H; de Bock GH; Nijman HW
    Int J Cancer; 2010 Mar; 126(6):1417-27. PubMed ID: 19728333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major histocompatibility complex (MHC)-I and MHC-II expression in Hodgkin's disease in relation to the presence of Epstein-Barr Virus (EBV).
    Tzardi M; Kouvidou C; Papakonstantinou E; Datseris G; Darivianaki K; Karidi E; Eliopoulos G; Delidis G; Rontogianni D; Kanavaros P
    Anticancer Res; 1996; 16(2):827-31. PubMed ID: 8687136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome.
    Simonitsch-Klupp I; Hauser I; Ott G; Drach J; Ackermann J; Kaufmann J; Weltermann A; Greinix HT; Skrabs C; Dittrich C; Lutz D; Pötter R; Mannhalter C; Lechner K; Chott A; Jaeger U
    Leukemia; 2004 Jan; 18(1):146-55. PubMed ID: 14603341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.